Division of Medical Oncology, BC Cancer Agency - Vancouver Cancer Centre, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada.
Urol Clin North Am. 2010 Feb;37(1):105-19, Table of Contents. doi: 10.1016/j.ucl.2009.11.011.
This article reviews the concepts and rationale behind targeted agents that are currently in clinical testing for patients with castration resistant prostate cancer (CRPC). Advances in our understanding of the molecular mechanisms underlying prostate cancer progression has translated into a variety of treatment approaches. Agents targeting androgen receptor activation and local steroidogenesis, angiogenesis, apoptosis, chaperone proteins, the insulinlike growth factor pathway, RANK ligand, endothelin receptors, and Src family kinases are entering, or have recently completed, accrual to phase III trials for patients with CRPC. There has also been interest generated by data from early-phase studies evaluating multitargeted tyrosine kinase inhibitors, agents effecting signal transduction pathways, and novel cytotoxics.
本文综述了目前用于去势抵抗性前列腺癌（CRPC）患者临床试验的靶向药物的概念和原理。我们对前列腺癌进展的分子机制的理解的提高已经转化为各种治疗方法。针对雄激素受体激活和局部甾体生成、血管生成、细胞凋亡、伴侣蛋白、胰岛素样生长因子途径、RANK 配体、内皮素受体和 Src 家族激酶的药物正在进入或最近已完成 CRPC 患者的 III 期临床试验。早期研究评估多靶点酪氨酸激酶抑制剂、影响信号转导途径的药物和新型细胞毒素的数据也引起了人们的兴趣。
